Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fibroid treatment showdown: which procedure stands the test of time?

NCT ID NCT02100904

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This nationwide registry follows 578 women with uterine fibroids who choose either radiofrequency ablation (Acessa) or myomectomy. Researchers track symptom changes, quality of life, and need for repeat treatment over three years. The goal is to understand which procedure provides better long-term relief and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiofrequency ablation (Acessa) or myomectomy
What this could lead to
If successful, this study could provide clear evidence on which fibroid treatment offers better long-term symptom relief and fewer repeat procedures.
What could go wrong
This is an observational registry, not a controlled trial, so results may be influenced by patient choice and other factors. It tracks outcomes but does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

578 people

The number who actually took part.

Start date

May 2014

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with uterine fibroids who are planning to undergo or have undergone radiofrequency ablation (Acessa) or myomectomy treatment.

Ages

21 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Planning to undergo or have undergone\* RF ablation (Acessa) or myomectomy (laparoscopic or abdominal) for treatment of uterine fibroids. * Able to give informed consent * Speak English or Spanish * Women enrolled at contracted clinical sites must enroll prior to their RF ablation treatment Exclusion Criteria: * \<21 years of age * Plan to undergo hysteroscopic myomectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uterine fibroids are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leiomyoma uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uterine fibroids

Contacts and locations

Locations

  • Acacia OBGYN

    San Antonio, Texas, 78217, United States

  • Dedicated to Women

    Dover, Delaware, 19904, United States

  • Duke University

    Durham, North Carolina, 27704, United States

  • Fibroid and Pelvic Wellness Center of Georgia

    Alpharetta, Georgia, 30005, United States

  • Gynecology Institute of Chicago

    Chicago, Illinois, 60605, United States

  • MacArthur Medical Center

    Irving, Texas, 75062, United States

  • Tassone Advanced Gynecology

    Austin, Texas, 78723, United States

  • UC Irvine Medical Center

    Irvine, California, 92868, United States

  • UT Southwestern

    Dallas, Texas, 75390, United States

  • University of California, San Diego

    San Diego, California, 92037, United States

  • University of California, San Francisco

    San Francisco, California, 94115, United States

  • Women's Healthcare Associates of IL, SC

    Homewood, Illinois, 60430, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.